Drug Trial Radar · NCT04333576
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain
Last checked: Nov 19, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
800
Planned (sponsor's estimate)
Start
Aug 10, 2020
Primary completion
Jul 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Apr 3, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 49 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Endometriosis is a painful disorder of the uterus affecting 6-10% of women of childbearing age. Endometriosis affects daily activities, social relationships, sexuality and sexual activity, and mental health. This study will evaluate how well elagolix in combination with combined oral contraceptives (COC) works within the body and/or how safe it is compared to placebo (does not contain treatment drug). This study will assess the dysmenorrhea (painful periods) response in participants with endometriosis and associated pain. Elagolix is an approved drug for the management of moderate to severe pain associated with endometriosis. Participants are randomly put in 1 of 3 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 3 chance that participants will be assigned to placebo. Adult female participants who still have periods with a diagnosis of endometriosis will be enrolled. Around 800 participants will be enrolled in the study at multiple sites in the United States, including Puerto Rico. Participants will receive oral elagolix or placebo tablets in combination with combined oral contraceptive (COC) or placebo capsules for 3 months. All the participants will receive elagolix tablets in combination with COC tablets from Month 4 through Month 18. There will be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Endometriosis
Interventions
ElagolixDrug
Tablet:Oral
PlaceboDrug
Tablet:Oral
Combined Oral ContraceptiveDrug
Tablet:Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Responders Based on Dysmenorrhea (DYS) Pain ScaleTime frame: Month 3
- Number of Participants Experiencing Adverse Events (AEs)Time frame: Up to approximately 50 months
Locations
179 sites in 2 countries. Site status is shown where the registry gives one.
Pinnacle Research Group /ID# 217062
Anniston, Alabama
ACCEL Research Sites /ID# 218044
Birmingham, Alabama
Alabama Clinical Therapeutics /ID# 217166
Birmingham, Alabama
Alabama Clinical Therapeutics /ID# 222301
Birmingham, Alabama
University of Alabama at Birmingham - Women's and Infant's Center /ID# 224503
Birmingham, Alabama
Trinity Research Group /ID# 246932
Dothan, Alabama
Southern Women's Specialists PC /ID# 217143
Fairhope, Alabama
Women's Health Alliance of Mobile /ID# 222591
Mobile, Alabama
Mobile, OBGYN P.C. /ID# 217135
Mobile, Alabama
North Valley Women's Care /ID# 217092
Glendale, Arizona
MomDoc Womens Health Research /ID# 221661
Phoenix, Arizona
Applied Research Center of Arkansas /ID# 248494
Little Rock, Arkansas
Unity Health- Searcy Medical Center /ID# 217050
Searcy, Arkansas
Diagnamics Inc. /ID# 225385
Encinitas, California
Atella Clinical Research /ID# 224024
La Palma, California
Valley Renal Medical Group Research /ID# 228614
Northridge, California
Futura Research, Org /ID# 217361
Norwalk, California
Northern California Research /ID# 217301
Sacramento, California
A & B Clinical Research /ID# 224471
San Diego, California
Advanced Clinical Research Center, LLC /ID# 248398
San Diego, California
Rocky Mountain Internal Medicine - Aurora /ID# 245161
Aurora, Colorado
Velocity Clinical Research - Denver /ID# 217297
Denver, Colorado
Boeson Research - Grand Junction /ID# 248580
Grand Junction, Colorado
Advanced Women's Health Institute /ID# 217150
Greenwood Village, Colorado
Red Rocks OB/GYN /ID# 217103
Lakewood, Colorado
Reproductive Assoc of Delaware /ID# 227764
Newark, Delaware
Medstar Health Research Institute /ID# 244937
Washington D.C., District of Columbia
James A. Simon, MD, PC /ID# 218116
Washington D.C., District of Columbia
Topaz Clinical Research /ID# 218615
Apopka, Florida
Ideal Clinical Research Inc. /ID# 218832
Aventura, Florida
Helix Biomedics, LLC /ID# 218649
Boynton Beach, Florida
Olympian Clinical Research /ID# 244426
Clearwater, Florida
Women's Medical Research Group /ID# 218524
Clearwater, Florida
Doral Medical Research, LLC /ID# 225146
Doral, Florida
Universal Axon Clinical Research /ID# 248553
Doral, Florida
KO Clinical Research, LLC /ID# 217173
Fort Lauderdale, Florida
Alliance for Multispecialty Research (AMR) - Fort Myers /ID# 217061
Fort Myers, Florida
Solutions Through Adv Rch /ID# 220973
Jacksonville, Florida
Care Partners Clinical Research /ID# 217042
Jacksonville, Florida
Vida Clinical Research /ID# 245325
Kissimmee, Florida
Showing 40 of 179 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.